Showing results (1781-1790 of 2,220) with videos related to
Sort By:
Pageof 222
BMC Medicine|July 13, 2022
Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countriesJohnny T K Cheung, Eric Lau, Cyrus C T Tsui, et al.Journal of Medicinal Chemistry|February 17, 2025
Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 SynthaseGebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, et al.The Journal of Infectious Diseases|May 20, 2011
Identification of human papillomavirus type 58 lineages and the distribution worldwidePaul K S Chan, Alfred C S Luk, Jong-Sup Park, et al.Nature Chemical Biology|May 24, 2016
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cellsMaia Vinogradova, Victor S Gehling, Amy Gustafson, et al.Plos One|April 23, 2021
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US VeteransCatherine G Derington, Jordana B Cohen, April F Mohanty, et al.Genome Research|July 11, 2006
Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringensGarry S A Myers, David A Rasko, Jackie K Cheung, et al.AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.Journal of Medicinal Chemistry|January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor ModelsMichael Berlin, Jennifer Cantley, Mark Bookbinder, et al.Pageof 222